Using artesunate to improve treatment outcomes for cervical precancer in HIV positive women
Official title: Feasibility of artesunate to improve HPV and cervical precancer treatment outcomes among HIV positive women in LMICs
Funded at Univ of North Carolina Chapel Hill · NIH-10922824 · Data updated 2026-11-12
This study is looking at whether a medication called artesunate can help improve cervical cancer treatments for women with HIV in low- and middle-income countries, aiming to reduce the chances of HPV infections coming back after standard treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 6, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $278,390 |
| NIH project number | 5R34CA284983-02 |
| Project ID | NIH-10922824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women living with HIV who are at risk for cervical precancer and reside in low- and middle-income countries.
✕Less likely to help
Patients who are not living with HIV or who do not have cervical precancer may not benefit from this research.
What this research studies
This research investigates the use of artesunate, a medication derived from artemisinin, to enhance the effectiveness of cervical precancer treatments in women living with HIV in low- and middle-income countries. The study aims to address the high rates of treatment failure and persistent HPV infections that these women face after standard treatments like ablation. By exploring the feasibility of artesunate, the research seeks to provide a new therapeutic option that could improve HPV clearance and reduce the recurrence of cervical intraepithelial neoplasia. Participants will be monitored for treatment outcomes and HPV status over time.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and reduced cervical cancer risk for HIV positive women in low-resource settings.
How similar studies have gone: Previous studies in the U.S. have shown safety and potential efficacy of artesunate for treating HPV-related lesions, suggesting promise for this approach.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Mungo, Chemtai — Univ of North Carolina Chapel Hill
- Study coordinator: Mungo, Chemtai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.